Cathepsin D (CD), the major intracellular aspartyl protease, is a mediator of IFN-g and TNF-a induced apoptosis. Using subtractive hybridization screening we isolated CD as an upregulated transcript in PA1 human ovarian cancer cells undergoing adriamycin-induced apoptosis. CD mRNA levels increased in wild-type p53-expressing PA1, ML1 leukemia and U1752 lung cancer cells but not in mutant p53-expressing cells following adriamycin exposure. Overexpression of CD inhibited growth of colon, liver, and ovarian cancer cells. CD protein expression was increased by exposure of ML1 cells to etoposide, adriamycin or g-radiation. Inhibition of CD protease with Pepstatin A suppressed p53-dependent apoptosis in lymphoid cells, suggesting a possible role for CD in p53-dependent cell death. CD 7/7 ®broblasts were found to be more resistant to killing by adriamycin and etoposide, as compared to CD +/+ cells. Two p53 DNA-binding sites located in the CD-promoter speci®cally bound to p53 protein in vitro and appeared to mediate transactivation of a CDpromoter luciferase-reporter during p53-dependent apoptosis. These observations link CD protease to p53-dependent tumor suppression and chemosensitivity.
Introduction
Activation of the p53 pathway in mammalian cells can lead to cell cycle arrest or apoptosis (Levine, 1997) . p53-dependent cell cycle arrest is believed to require transcriptional activation of the cyclin-CDK inhibitor p21 WAF1/CIP1 (El-Deiry et al., 1993 Harper et al., 1993 Xiong et al., 1993) and may involve other mechanisms (Deng et al., 1995; Fiscella et al., 1997) . The activation of apoptosis by p53 is less well understood, but is believed to involve both transcriptional as well as transcription-independent mechanisms (Caelles et al., 1994; Haupt et al., 1995; Sabbatini et al., 1995; Attardi et al., 1996; Walker and Levine, 1996) . Abnormalities of p53-dependent apoptosis have been found to contribute to tumor development (Symonds et al., 1994) , tumor progression (Kinzler and Vogelstein, 1996) , and chemotherapeutic drug resistance (Lowe et al., 1993; Weinstein et al., 1997; Wu and El-Deiry, 1996a,b) . Perhaps the best characterized mediator of p53-dependent apoptosis by a transcriptional mechanism is the bcl2-family member bax (Miyashita and Reed, 1995; Oltvai et al., 1993) . Bax 7/7 ®broblasts have been shown to have decreased apoptosis following DNA damage (McCurrach et al., 1997) and recent experiments have provided evidence that bax may function as a tumor suppressor gene (Rampino et al., 1997; Yin et al., 1997) . However, there is evidence that bax function is not sucient to account for p53's role in apoptosis or chemosensitivity (McCurrach et al., 1997; Yin et al., 1997; Knudson et al., 1995) . We therefore sought to identify novel mediators of p53-dependent apoptosis.
We previously found that exogenous expression of the human papilloma virus E6 protein in several PA1 human ovarian cancer cell clones resulted in greater than 100-fold increased resistance to killing by multiple chemotherapeutic agents including carboplatin, taxol, etoposide and adriamycin (Wu and El-Deiry, 1996b) . We used the chemosensitive PA1-neo cells to isolate genes whose expression is increased by the chemotherapeutic agent adriamycin. As a control (driver) for the subtractive hybridization screening (see Materials and methods), we used transcripts from untreated PA1-neo cells and adriamycin-treated PA1-E6 cells. Our hypothesis was that part of the mechanism of apoptosis by p53 may involve transcriptional activation of target genes other than bax that may be involved in apoptosis induction following exposure of chemosensitive cancer cells to adriamycin.
We now describe the isolation of Cathepsin D (hereafter referred to as CD) as a p53-regulated gene which may play a role in p53-dependent apoptosis. In addition, we report that CD may be a determinant of chemosensitivity because we found that CD 7/7 cells have increased resistance to killing by either adriamycin or etoposide as compared to CD +/+ cells. The results suggest that CD protease may be a novel mediator of a subset of the biological eects of p53.
Results and discussion
Our previous work showed that p53 status correlates with chemosensitivity in PA1 ovarian cancer cells (Wu and El-Deiry, 1996b) . Targeting p53 for degradation by the HPV type16 E6 gene in PA1 cells led to the development of resistance to the cytotoxic eects of chemotherapeutic agents (Wu and El-Deiry, 1996b ). In order to isolate genes that may mediate cell death in the chemosensitive cells, we constructed a cDNA library from PA1 cells following 10 h of exposure to a cytotoxic dose of doxorubicin and screened the library using subtractive hybridization (see Materials and methods). A total of 100 clones which hybridized more to the subtracted probe as compared to the control probe were initially picked. Only six of those genes were upregulated following adriamycin treatment of PA1 cells. p21 was one of the six clones picked and its isolation validated the screen as capable of detecting genes whose expression is known to be increased following adriamycin exposure (El-Deiry, 1994) . CD is a known gene that was isolated. The other target genes picked will be described elsewhere (Figure 1) .
CD is the major cellular aspartyl protease, and has recently been isolated from HeLa cells as a mediator of programmed cell death induced by IFN-g, Fas/APO-1 and TNF-a (Deiss et al., 1996) . CD mRNA levels were signi®cantly elevated in PA-1, ML1 leukemia cells and U1752 lung cancer cells following adriamycin treatment ( Figure 2 ). Although the correlation was not perfect, analysis of CD mRNA levels in several human cancer cell lines before and after adriamycin exposure suggested the possibility that CD may be a p53-regulated gene (Figure 2a ). Using wild-type p53 expressing ML1 cells we found that CD protein levels increased following exposure to either adriamycin, etoposide (Figure 2b ) or increasing doses of gradiation (Figure 2c ). These experiments demonstrate that expression of CD protein is inducible by DNAdamaging agents.
Because CD expression has been recently found to contribute to cytokine-induced apoptosis (Deiss et al., 1996) , we investigated the primary eect of CD overexpression on cancer cell growth. Using colony formation assays, we found that overexpression of CD inhibited the growth of human colon (HCT116 and SW480), liver (HepG2) and ovarian (SKOV3) cancer cells ( Figure 3 and data not shown). Exogenous CD inhibited growth of SKOV3 despite their elevated endogenous CD levels (Figure 2a) , suggesting that the endogenous gene product may be defective in growth inhibition, and that overexpression per se is not sucient to kill the cells.
In order to ascertain whether CD activation may be required for induction of p53-dependent apoptosis, we examined the eects of Pepstatin A on apoptosis in a murine lymphoma cell line (M3) which expresses a ts p53 protein and undergoes apoptosis at the permissive temperature (Wang et al., 1993) . Pepstatin A, an inhibitor of acid proteases, has been used previously to demonstrate a role for CD in cytokine-induced cell death (Deiss et al., 1996) . Incubation of M3 cells in the presence of 100 mM Pepstatin A had no eect on cell viability at the 378C nonpermissive temperature (not shown). Upon shift to 328C, M3 cells underwent massive apoptosis, as previously reported (Wang et al., 1993; Figure 4a,b) . Pepstatin A inhibited by approximately 50% the extent of p53-dependent apoptosis in M3 cells (Figure 4a,b) . These results suggest that CD expression may play a role in p53-dependent apoptosis in lymphoid cells.
Since CD expression was increased in cells exposed to DNA-damaging agents, we evaluated the role of CD as a determinant of chemosensitivity. We found a twofold increased resistance to adriamycin and a greater than tenfold increased resistance to etoposide of CD 7/7 as compared to CD +/+ cells (Figure 5a ,b). We con®rmed that CD 7/7 cells stabilized p53 protein upon exposure to either adriamycin or etoposide (Figure 5c ), consistent with the presence of wild-type p53 protein. We speculate that a greater dierence in chemosensitivity between CD +/+ and CD 7/7 cells was observed following etoposide vs adriamycin exposure may be due to a lesser dependence on p53 and doublestrand breaks in killing by adriamycin. The results support the hypothesis that the pathway of DNAdamage-induced p53-dependent cell death may be defective in CD 7/7 cells and demonstrate that CD may be a determinant of DNA-damage induced chemosensitivity.
We wished to determine whether CD upregulation is a direct consequence of p53 action or perhaps a downstream event in the apoptosis pathway. Examination of the promoter sequence of CD revealed the presence of two candidate p53 DNA-binding sites (Augereau et al., 1994) . Electrophoretic mobility shift assays revealed that either site could be bound speci®cally by p53 protein and could be supershifted by anti-human p53 antibody (Figure 6a ). In addition, either site appeared to compete for p53 binding to a response element present in the p21 promoter ( Figure  6b ). These results provide evidence for a direct interaction between the p53 protein and potential regulatory DNA sequences located upstream of the human CD gene. In order to determine if the putative CD activation by p53 might occur in the absence of DNA damage, we examined CD expression in M3 upon shifting the cell culture to the wild-type p53 permissive temperature (Figure 7a ). CD mRNA levels increased within 24 h following shift of M3 cells to 328C, in a manner similar to p21. These results suggested that CD may be directly regulated by p53 in the absence of DNA damage, and that expression of the murine CD gene could be upregulated by p53. To determine if CD regulation by p53 occurs at the level of transcription, we constructed a CD promoter-luciferase reporter (CD-Luc) plasmid. Luciferase activity increased 20-fold following transfection of pCD-Luc and temperature shift to 328C (Figure 7b) . A similar although greater induction was observed with a p21 promoterluciferase reporter (WWP-Luc; El-Deiry et al., 1993) at the permissive temperature (Figure 7b ). Deletion of both p53 sites from the CD promoter-luciferase reporter abrogated the p53-dependent increase in luciferase activity (Figure 7c ). These results suggest that p53 could transactivate CD gene expression in lymphoma cells undergoing apoptosis. In the future it should be possible to perform a more detailed mutational analysis of the CD promoter to more precisely de®ne the dependence on p53 in transactivation.
In summary, we have evidence for transcriptional activation of the CD gene in lymphoid cells undergoing p53-dependent apoptosis. CD activation by p53 appears to be directly mediated through p53-speci®c DNA-binding sites located in the CD promoter. Although CD may contribute to apoptosis by p53, its activity is not absolutely required and the precise mechanism of the apoptosis is not clear, i.e. its subcellular localization when it is overexpressed and the targets for its protease activity remain unclear. However, cells which completely lack expression of CD exhibit increased resistance to killing by chemotherapeutic drugs. The present results provide a direct link between the tumor suppressor p53 and a cellular protease involved in cell death and raise the possibility that other transcription factors that induce apoptosis may similarly regulate expression of proteases.
Materials and methods

Cell culture and transfections
The culture conditions for all human cancer cell lines used have been previously described (Wu and El-Deiry, 1996a; Zeng et al., 1997) . The M3 murine lymphoma cell line expressing temperature-sensitive p53 has been described (Wang et al., 1993) . CD +/+ and CD 7 / 7 ®broblasts were isolated and cultured as previously described (Saftig et al., 1995) . Transfections were carried out as previously described (Zeng et al., 1997) . Chemotherapeutic drug treatments were performed as described (Wu and ElDeiry, 1996a) . g-irradiation of cells was carried out as previously described (El-Deiry et al., 1994) .
Subtractive hybridization screening
PA1-neo ovarian teratocarcinoma cells (Wu and El-Deiry, 1996b) were incubated for 10 h in the presence of 0.3 mg/ml adriamycin. A cDNA library was constructed using poly(A) + RNA prepared from the adriamycin treated cells. The library was prepared and screened using previously described methods (El-Deiry et al., 1993) . Figure 6 Binding of human p53 to two dierent binding sites in the CD promoter. Electrophoretic mobility shift (arrows) or supershift (long arrow) using candidate DNA-binding sites from the human CD (CD) promoter (a) or a p53 DNA-binding site from the human p21 promoter (b) as probes for binding in the presence of baculovirus expressed p53 (as indicated by`+'). Competitor DNA was used to demonstrate speci®c binding to p53 (amounts of competitor relative to probe as indicated; the p21 site = speci®c competitor for CD sites (a), either CD site = speci®c competitor for the p21 site (b) and a c-myc DNA binding site = nonspeci®c competitor for p21 or CD sites). Anti-human p53 speci®c monoclonal Ab 421 was included in some assays (as indicated by`+') to demonstrate the presence of p53 protein in the shifted bands. Both sites always gave supershift bands. Mobility shift assays were performed as described in Materials and methods Brie¯y, a total of 50 000 plaques were dierentially screened by hybridization to: (Levine, 1997) a cDNA probe prepared from equal portions of RNA isolated from untreated PA1-neo cells and PA1-E6 cells (Wu and ElDeiry, 1996b ) and compared with a subtracted probe prepared by using 500 ng cDNA from adriamycin treated PA1-neo cells as target and a total of 20 mg driver poly(A) + RNA (10 mg from untreated PA1-neo cells and 10 mg from adriamycin treated PA1-E6 cells). A total of 100 clones were picked in the primary screen, and of those 30 were picked from the secondary screen because they showed reproducible dierential hybridization to subtracted and control probes. Six unique cDNA's isolated from the secondary screen demonstrated upregulation of their mRNA by Northern analysis + adriamycin treatment of PA1 cells. The p21 and CD cDNA's were two known genes out of the six. The other adriamycin-induced transcripts are novel and their characterization will be described elsewhere.
Plasmids
A full length human CD cDNA clone was obtained from the initial library screen (pZL-CD). The 2.0 kb CD cDNA was subcloned as a NotI fragment into the NotI site of the pCEP4 vector (Invitrogen) in either the sense (CD-Sense) or antisense (CD-Antisense) orientation. CD protein expression was veri®ed following transient transfection of SW480 and HCT116 cells (not shown). A 780 bp fragment of the human CD promoter was ampli®ed from human genomic DNA isolated from HCT116 cells using the following primers: 5'-ATCCCAAGCTTTCTAGAAAAC' and 5'-TA-CGCGTCGACCGGGATGACGCCGCAGTTG-3' and the following PCR conditions: 958C for 30 s, 488C for 1.5 min, 728C for 1 min 6 40 cycles followed by a 5 min incubation at 728C. The 3'-end of this fragment is 50 bp upstream of CD translation initiation. A fragment of 480 bp was then ampli®ed using the 780 bp sequence (subcloned into a chloramphenicol-resistant plasmid) as template and the following primers: 5'-ATCCCAAGCTTATTCGGTGG-GCTGGGG-ACT-3' and 5'-TACGCGTCGACCGGGAT-GACGCCGCAGTTG-3' (same 3'-end as the 780 bp fragment) and the following PCR conditions: 958C for 30 s, 598C for 1.5 min, 728C for 1.5 min630 cycles followed by a 5 min incubation at 728C. Other PCR conditions were as previously described (El-Deiry et al., 1993) . The ampli®ed genomic fragment was subcloned as a SalI/HindIII fragment into the WWP-Luc vector (El-Deiry et al., 1993) Lysates were prepared 24 h later and luciferase assays were performed as previously described (El-Deiry et al., 1993) promoter region spanning 7530 to 749, upstream of translation initiation, containing candidate p53 DNA binding sites 1 and 2 (Augereau et al., 1994) . The D-CDLuc vector (CD-Luc lacking a 280 bp region containing p53 DNA-binding sites 1 and 2) was constructed by PCR ampli®cation and subcloning as for CD-Luc except that the following PCR primers were used: 5'-ATCCCAAGCT-TGCGCGAGCGGCGGGAACTG-3' and 5'-TACGC-GTCGA-CCGGGATGACGCCGCAGTTG-3', containing the same 3' end of the CD promoter as in CD-Luc.
Northern and Western blotting
Northern blotting was performed as previously described (El-Deiry et al., 1993) . A full-length (2.0 kb) human CD cDNA probe was generated by digestion of the pZL-CD clone with EcoRI. A 600 bp mouse CD genomic probe covering exons 7 and 8 was generated by digesting plasmid pCD12 (Saftig et al., 1995) with XbaI and BamHI. A 2.0 kb mouse-p21 probe was generated by digestion of pZL-mouse-WAF1 with EcoRI. Western blotting was performed using a mouse anti-human CD monoclonal antibody (Ab1; Oncogene Science) or a sheep anti-mouse p53 polyclonal antibody (Ab-7; Oncogene Science) as previously described (El-Deiry et al., 1994) .
CD growth inhibition and chemosensitivity assays SW480, SKOV3, HepG2 and HCT116 cells were transfected with pCEP4, CD-Sense or CD-Antisense plasmids as described above. At 1 day after transfection selection was begun in the continuing presence of hygromycin (0.25 mg/ml for SW480, SKOV3 and HepG2 cells or 0.1 mg/ml for HCT116 cells) and colony formation assays were performed on day 10 as previously described (El-Deiry et al., 1993) . For the chemosensitivity assays a total of 5000 CD +/+ or CD 7 / 7 ®broblasts were plated per well in 24 well plates. On the next day, incubation was begun at various concentrations of chemotherapeutic drugs (see Figure 5 ). Drug selection was continued for 1 week during which time dying cells detached and¯oated in the media. The number of adherent cells was determined as described (Wu and El-Deiry, 1996a ).
Apoptosis assays
Overnight cultured ts p53 val135 -expressing M3 lymphoma cells were either maintained at 378C or shifted to 328C, which induces a massive p53-dependent apoptosis (Wang et al., 1993) . The protease inhibitor Pepstatin A (0.1 mM; Sigma) was added into the medium in some experiments as shown in Figure 4 . After 48 h incubation either at 378C or 328C with or without Pepstatin A, cells were harvested, ®xed and stained with DAPI (Sigma). the number of DAPI + apoptotic nuclei was determined by counting 500 ± 1000 cells (for each condition in each experiment, in a blinded fashion) under U.V.-microscopy as described (Wu and El-Deiry, 1996a ).
Electrophoretic mobility shift assays
A genomic fragment containing 830 bp of upstream regulatory region of the CD gene has been previously cloned (Augereau et al., 1994) . Examination of the sequence revealed two candidate p53 sites: the sequence of Site 1 which is contained between 7275 and 7257 upstream of the ATG is 5'-AAGCTGGGCCGGGCT-GACC-3'. The sequence of site 2 which is contained between 7503 and 7487 upstream of the ATG is 5'-AACCTTGGTTTGCAAAG-3'. The homology to the p53 consensus sequence (El-Deiry et al., 1992) was 75% for site 1 and 65% for site 2, including conservation of the 4th C and 7th G within each p53 half-site. Electrophoretic mobility shift assays were carried as previously described with the following changes. The mouse anti-human p53 monoclonal antibody pAb421 (Ab1: Oncogene Science) was used to demonstrate the presence of p53 in CD promoter site band shifts. The sequence of the CD probes were: site 1: 5'CCC-CAGAAGCTGGGCCGGGCTGACCCCGCGG-3' and site 2: 5'-TGAATTTAACCTTGGTTTGCAAGAGG-CTTC-3'. The sequence of the p21 binding site used was 5' -CAGGAACATGTCCCAACATGTTGAGC -3'. Only 100 ng of poly(dI-dC) was used to inhibit non-speci®c binding to the labeled probes. For the supershift assays, the anti-p53 antibody was preincubated for 1 h with the baculovirus-expressed human p53 prior to addition of the labeled probe and poly(dI-dC).
We recently observed that in SW480 human colon adenocarcinoma cells cotransfection of CD-Luc and pCEP4-wt p53 resulted in complete suppression of luciferase activity as compared to cells cotransfected with CD-Luc and the pCEP4 vector control. Because there is evidence that Cathepsin D overexpression contributes to the development of tumor metastases and that p53 mutations are more common in metastatic lesions, we hypothesize that in epithelial cancer cells, in the absence of DNA damage which leads to apoptosis and p53 phosphorylation, p53 may normally repress Cathepsin D expression in a pathway of metastasis suppression.
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